Results 71 to 80 of about 284,324 (192)

Development of oncolytic viruses for cancer therapy

open access: yes, 2021
Oncolytic virotherapy is a therapeutic approach that uses replication-competent viruses to kill cancers. The ability of oncolytic viruses to selectively replicate in cancer cells leads to direct cell lysis and induction of anticancer immune response ...
Poh, Chit Laa *, Noraini Abd Aziz, *
core   +1 more source

Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells

open access: yesFrontiers in Pharmacology, 2017
Oncolytic viral therapy, which makes use of replication-competent lytic viruses, has emerged as a promising modality to treat malignancies. It has shown meaningful outcomes in both solid tumor and hematologic malignancies.
Dhaval S. Sanchala   +2 more
doaj   +1 more source

Infant Embryonal CNS Tumors: Molecular Insights and Treatment Considerations for Contemporary Pediatric Neuro‐Oncology

open access: yesPediatric Blood &Cancer, Volume 73, Issue 11, November 2026.
ABSTRACT Background Embryonal tumors comprise the majority of malignant central nervous system (CNS) neoplasms diagnosed in children under 3 years of age. Compared with their counterparts in older children, these tumors exhibit distinct molecular biology and a more aggressive clinical phenotype, while their management is complicated by the heightened ...
Sudarshawn Damodharan   +3 more
wiley   +1 more source

Oncolytic viruses in malignant pleural mesothelioma

open access: yes, 2022
Mesothelioma is an aggressive cancer of the serosal membranes with a median survival of 9 to 12 months. Oncolytic viruses are a next-generation therapy. The viruses directly lyse cancer cells and prime the immune system.
Ladhar, Pamelbir
core   +1 more source

Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer

open access: yesMedComm, Volume 7, Issue 10, October 2026.
Mesothelin overexpression activate important pathways like nuclear factor k‐light‐chain‐enhancer of activated B cells (NF‐κB) and interleukin‐6 (IL‐6). This in turn causes numerous cancers, such as pancreatic and ovarian cancers. MSLN‐targeting immunotherapies, like monoclonal antibodies, have shown efficacy.
Manoj Kumar Gupta   +2 more
wiley   +1 more source

Characterization of Oncolytic Herpesviruses [PDF]

open access: yes, 2008
Oncolytic viruses are able to selectively replicate in tumour cells and are an attractive new avenue of cancer therapy that lacks the toxic side effects of current treatment modalities. HSV-1 mutants lacking ICPO are promising oncolytic vectors, however,
Rodrigues, Rebecca
core  

The impact of innate immune response on the efficacy of oncolytic viruses

open access: yesВопросы вирусологии
Oncolytic viruses represent a promising class of immunotherapeutic agents for the treatment of malignant tumors. The proposed mechanism of action of various oncolytic viruses has initially been explained by the ability of such viruses to selectively lyse
Kirill N. Trachuk   +3 more
doaj   +1 more source

Targeting Nucleotide Biosynthesis: A Strategy for Improving the Oncolytic Potential of DNA Viruses

open access: yesFrontiers in Oncology, 2017
The rapid growth of tumors depends upon elevated levels of dNTPs, and while dNTP concentrations are tightly regulated in normal cells, this control is often lost in transformed cells.
Chad R. Irwin   +5 more
doaj   +1 more source

The evolving role of immunotherapy in ovarian cancer

open access: yesCancer, Volume 132, Issue 18, 15 September 2026.
Abstract Ovarian cancer remains a major cause of gynecologic cancer mortality; and, although immune checkpoint inhibitors have transformed treatment in other solid tumors, their activity in ovarian cancer has been limited by tumor heterogeneity, an immunosuppressive tumor microenvironment, and the lack of robust predictive biomarkers.
Ana Carolina Veneziani   +2 more
wiley   +1 more source

Superantigens in Cancer Immunotherapy: Mechanisms, Engineering Strategies, and Therapeutic Potential

open access: yesThe FASEB Journal, Volume 40, Issue 17, 15 September 2026.
Schematic overview of superantigen‐mediated antitumor immune responses and immune suppression within the tumor microenvironment. (1) Antigen‐presenting cells activate T cells through MHC‐II/TCR interactions resulting in the production of cytokines (2) The pro‐inflammatory cytokines released by activated immune cells stimulate downstream immune ...
Urooj Yousaf Virk   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy